Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993
Debt
Debt-to-Equity RatioN/A
Current Ratio12.64
Quick Ratio12.63
Price-To-Earnings
Trailing P/E Ratio-6.74
Forward P/E Ratio-6.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales474.12
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book4.70
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-63.20%
Return on Assets-42.19%
Miscellaneous
Employees21
Outstanding Shares13,170,000
Spring Bank Pharma (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharma's stock symbol?
Spring Bank Pharma trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharma's earnings last quarter?
Spring Bank Pharma (NASDAQ:SBPH) issued its quarterly earnings data on Friday, April, 27th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.15. View Spring Bank Pharma's Earnings History.
What price target have analysts set for SBPH?
4 brokerages have issued 1 year price targets for Spring Bank Pharma's stock. Their forecasts range from $30.00 to $32.00. On average, they anticipate Spring Bank Pharma's share price to reach $30.6667 in the next year. View Analyst Ratings for Spring Bank Pharma.
Who are some of Spring Bank Pharma's key competitors?
Some companies that are related to Spring Bank Pharma include Progenics Pharmaceuticals (PGNX), Insys Therapeutics (INSY), Kura Oncology (KURA), Akebia Therapeutics (AKBA), Aclaris Therapeutics (ACRS), Geron (GERN), Five Prime Therapeutics (FPRX), Aduro BioTech (ADRO), Keryx Biopharmaceuticals (KERX), Prothena (PRTA), Beyondspring (BYSI), ChemoCentryx (CCXI), Achaogen (AKAO), Cara Therapeutics (CARA) and Obseva (OBSV).
Who are Spring Bank Pharma's key executives?
Spring Bank Pharma's management team includes the folowing people:
- Mr. Martin J. Driscoll, Chairman, Pres & CEO (Age 59)
- Mr. Jonathan P. Freve, CFO & Treasurer (Age 40)
- Dr. Nezam H. Afdhal M.D., Chief Medical Officer (Age 61)
- Dr. Radhakrishna P. Iyer Ph.D., FRSC, Co-Founder, Chief Scientific Officer & Director (Age 68)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharma IPO?
(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.
Has Spring Bank Pharma been receiving favorable news coverage?
Media headlines about SBPH stock have been trending positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spring Bank Pharma earned a coverage optimism score of 0.42 on Accern's scale. They also assigned news headlines about the company an impact score of 46.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Spring Bank Pharma's major shareholders?
Spring Bank Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BVF Inc. IL (6.31%), Morse Asset Management Inc (1.28%), Millennium Management LLC (0.70%) and C WorldWide Group Holding A S (0.66%). Company insiders that own Spring Bank Pharma stock include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Institutional Ownership Trends for Spring Bank Pharma.
Which institutional investors are selling Spring Bank Pharma stock?
Which institutional investors are buying Spring Bank Pharma stock?
SBPH stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morse Asset Management Inc and BVF Inc. IL. Company insiders that have bought Spring Bank Pharma stock in the last two years include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Insider Buying and Selling for Spring Bank Pharma.
How do I buy shares of Spring Bank Pharma?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharma's stock price today?
One share of SBPH stock can currently be purchased for approximately $12.60.
How big of a company is Spring Bank Pharma?
Spring Bank Pharma has a market capitalization of $158.15 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharma employs 21 workers across the globe.
How can I contact Spring Bank Pharma?
Spring Bank Pharma's mailing address is 86 SOUTH STREET, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharma (SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharma and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
